Found: 10
Select item for more details and to access through your institution.
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD‐negative remission.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. E408, doi. 10.1002/ajh.26698
- By:
- Publication type:
- Article
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 12, p. 1382, doi. 10.1002/ajh.25647
- By:
- Publication type:
- Article
Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma.
- Published in:
- European Journal of Haematology, 2017, v. 98, n. 3, p. 263, doi. 10.1111/ejh.12826
- By:
- Publication type:
- Article
CT-046: Post-Transplant Cyclophosphamide in HLA-Matched and Haploidentical Transplant Recipients Receiving a Myeloablative Fractionated Busulfan Conditioning Regimen: Results of a Phase II Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S446, doi. 10.1016/S2152-2650(21)01992-3
- By:
- Publication type:
- Article
Poster: CT-046: Post-Transplant Cyclophosphamide in HLA-Matched and Haploidentical Transplant Recipients Receiving a Myeloablative Fractionated Busulfan Conditioning Regimen: Results of a Phase II Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S258, doi. 10.1016/S2152-2650(21)01627-X
- By:
- Publication type:
- Article
Improved Acute Graft-versus Host Disease (aGVHD) and Progression Free Survival with Post-Transplant Cyclophosphamide in AML/MDS Patients (pts) with Prior CTLA-4 or PD-1 Blockade.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S11, doi. 10.1016/j.clml.2017.09.038
- By:
- Publication type:
- Article
Novel Complex I inhibitor IACS-010759 Targets Leukemia Initiating Cells (LICs) in AML Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S297, doi. 10.1016/j.clml.2017.07.089
- By:
- Publication type:
- Article
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01229-z
- By:
- Publication type:
- Article
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-26282-z
- By:
- Publication type:
- Article
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.
- Published in:
- 2020
- By:
- Publication type:
- journal article